Skip to content
MARKETS / NYSE / ACH
NYSE · WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES · LARGE CAP

Accendra Health Inc. ACH

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.8B
▲ 3.1% YoY
$-1.1B
$-292.7M
In brief

What this company does

Accendra Health provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies, and provides integrated home healthcare equipment and related services in the U.S. It offers products and services for in-home care across diabetes treatment, home respiratory therapy, including home oxygen and non-invasive ventilation services, and obstructive sleep apnea treatment, including continuous positive airway pressure and bi-level positive airway pressure devices. It also supplies other home medical equipment and patient care product lines, including ostomy, wound care, urology, and incontinence products. Its revenues are generated through fee-for-service and capitation arrangements with government and commercial payors for equipment, supplies, services and other items rented and sold to patients. At the end of 2025, following the sale of its Products & Healthcare Services segment, it employed over 6,500 full-time and part-time teammates. Its brands include Apria and Byram Healthcare, which together bring nearly 90 years of combined experience. It is headquartered in Richmond, Virginia. Accendra Health, Inc. was formerly known as Owens & Minor, Inc.

Written from the business description in ACCENDRA HEALTH INC/VA/'s annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.

Growth
USD 2.8B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.8 · Net income -1.1
4B8B2008201120142017202020232025
Compound annual growth
−34.8%
−20.1%
−11.9%
−6.9%
−77.3%
−60.3%
−35.5%
+73.5%
−19.0%
−9.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −20.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−40 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 1.0% · Net -39.8%
2%4%-10%-20%-30%2008201120142017202020232025
ROE
FY2025 · ROE -1755.6%
-500%-1000%-1500%2008201120142017202020232025

Each USD of equity lost 1756 cents this year.

Cash & shareholders
USD 10.2M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -292.7
200M400M-100M-200M2008201120142017202020232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 10.2
50M100MDividendsNet buybacks200820102012201420162018202020222025

USD 10.2M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 2.5B
EquityUSD -461.0M
CashUSD 282.0M
Gross debtUSD 2.0B
Net debtUSD 1.8B
Current ratio0.58×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B2.82.72.610.09.88.59.29.49.39.79.89.49.18.98.68.18.07.2
Operating income $B0.0−0.20.10.10.40.20.1−0.40.10.20.20.20.20.20.20.20.20.2
EBITDA $B0.2−0.00.30.40.50.30.2−0.30.10.30.30.20.20.2····
Income tax $B0.00.00.0−0.00.10.0−0.0−0.0−0.00.10.10.10.10.10.10.10.10.1
Net income $B−1.1−0.4−0.00.00.20.0−0.1−0.40.10.10.10.10.10.10.10.10.10.1
Free cash flow $B−0.3−0.00.60.20.10.30.10.10.00.20.2−0.10.10.20.00.10.20.0
EPS, diluted $−14.31−4.73−0.530.292.940.47−1.03−7.281.201.761.651.061.761.721.811.751.671.50
Dividend / sh $····0.010.010.010.861.031.021.011.000.960.880.800.710.610.53
Payout %··−0002−8−1187586295555144403735
ROE %−1755.6−47.4−4.32.426.95.1−12.7−57.07.2·10.46.611.111.513.013.614.413.5
Shares out B0.080.080.080.080.080.070.060.060.060.060.060.060.060.060.060.060.06·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 86 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 8 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityWholesale-Medical, Dental & Hospital Equipment & Supplies
Listed onNYSE
Incorporated inVirginia
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image